Shenzhen Hepalink Pharmaceutical Group (09989) reported a net profit attributable to shareholders of RMB394 million for the first three quarters, down 28.84% year on year.
Shenzhen Hepalink Pharmaceutical Group (09989) announced its results for the first three quarters of 2026. The group recorded operating revenue of RMB3.797 billion, down 9.48% year on year; net profit attributable to shareholders of the listed company was RMB394 million, down 28.84% year on year; basic earnings per share were RMB0.2685.
Shenzhen Hepalink Pharmaceutical Group (09989) announced its results for the first three quarters of 2026. The Group recorded operating revenue of RMB3.797 billion, down 9.48% year on year; net profit attributable to shareholders of the listed company was RMB394 million, down 28.84% year on year; basic earnings per share were RMB0.2685.
Related Articles
Jiangsu Hengrui Pharmaceuticals (01276): Marketing authorization application for trastuzumab rezetecan for injection accepted and included in priority review process
Hua Hong Grace Semiconductor (01347): Chairman and President proposes share repurchase of the company's A-shares
CHINARES PHARMA (03320): China Resources Boya Bio-pharmaceutical Group's net profit for the first three quarters was RMB60.5883 million, a year-on-year decrease of 82.34%
Jiangsu Hengrui Pharmaceuticals (01276): Marketing authorization application for trastuzumab rezetecan for injection accepted and included in priority review process
Hua Hong Grace Semiconductor (01347): Chairman and President proposes share repurchase of the company's A-shares
CHINARES PHARMA (03320): China Resources Boya Bio-pharmaceutical Group's net profit for the first three quarters was RMB60.5883 million, a year-on-year decrease of 82.34%
